Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients with this condition.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema that works by blocking the bradykinin B2 receptor pathway.

- Acute hereditary angioedema type I: provides rapid relief of swelling during an attack. - Acute hereditary angioedema type II: reduces the severity and duration of edema episodes. - Hereditary angioedema of any type: helps control life‑threatening airway obstruction when administered promptly.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling at injection site: mild local reaction. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. - Dizziness: temporary light‑headedness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Airway angioedema: swelling of the throat or tongue that may compromise breathing. - Severe hypotension: sudden drop in blood pressure. - Urticaria: widespread hives. - Necrosis at injection site: tissue death at the injection area. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following precautions: - Pregnancy: safety not established; use only if the potential benefit justifies the risk. - Breastfeeding: unknown effects on the infant; weigh benefits against possible risks. - Renal impairment: no dosage adjustment required, but monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; monitor for enhanced angioedema. - Hypersensitivity: discontinue immediately if an allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines. Review the following interaction categories:

Major Interactions (Avoid): - ACE inhibitors: may reduce therapeutic effectiveness and increase angioedema risk. - Other bradykinin B2 antagonists: additive pharmacologic effect; avoid simultaneous use. - C1‑inhibitor concentrates given concurrently: may interfere with intended action.

Moderate Interactions (Monitor Closely): - NSAIDs: can potentiate angioedema; monitor for swelling. - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema; observe closely. - Diuretics: may affect fluid balance; watch for hypotension.